Suchergebnisse - "Penso, Laëtitia"

PubPharm (17)

1

Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis : a nationwide cohort study from the French Health Insurance Database (SNDS)

enthalten in: RMD open | 2024

von Bastard, L. | Claudepierre, P. | Penso, L. | +2

2

Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis : a cohort study of 14 778 patients from the French health insurance database (SNDS)

enthalten in: RMD open | 2023

von Pina Vegas, L. | Penso, L. | Sbidian, E. | +1

ErratumIn: RMD Open. 2024 Jan 12;10(1):. - PMID 38216291

3

Persistence of second-line biologics in psoriasis after first-line biologic failure : a nationwide cohort study from the French health insurance database (SNDS)

enthalten in: The British journal of dermatology | 2023

von Marcombes, C. | Penso, L. | Weill, A. | +3

CommentIn: Br J Dermatol. 2023 Sep 06;:. - PMID 37671667

4

First-Line Persistence of Biologics in Psoriasis from a Cohort Based on French Medico-Administrative Data

enthalten in: The Journal of investigative dermatology | 2023

von Marcombes, C. | Penso, L. | Sbidian, E.

5

Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19 : a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France

enthalten in: Annals of the rheumatic diseases | 2023

von Sbidian, E. | Penso, L. | Herlemont, P. | +7

CommentOn: Ann Rheum Dis. 2020 Oct;79(10):1386-1388. - PMID 32381561

6

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database

enthalten in: JAMA dermatology | 2022

von Pina Vegas, L. | Penso, L. | Claudepierre, P. | +1

ErratumIn: JAMA Dermatol. 2023 Oct 18;:. - PMID 37851435

7

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis : a nationwide cohort study

enthalten in: Rheumatology (Oxford, England) | 2022

von Pina Vegas, L. | Le Corvoisier, P. | Penso, L. | +3

CommentIn: Rheumatology (Oxford). 2022 Apr 11;61(4):1305-1306. - PMID 34508550

8

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2022

von Sbidian, E. | Penso, L. | Meyer, A.

CommentOn: Arthritis Rheumatol. 2022 Feb;74(2):244-252. - PMID 34279061

9

Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors : A Nationwide Population-Based Study Using the French National Health Data System

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2022

von Penso, L. | Bergqvist, C. | Meyer, A. | +5

CommentIn: Arthritis Rheumatol. 2022 Mar;74(3):547-548. - PMID 34463052

10

Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin‐17 Inhibitors : A Nationwide Population‐Based Study Using the French National Health Data System

enthalten in: Arthritis & Rheumatology | 2022

von Penso, L. | Bergqvist, C. | Meyer, A. | +5